267 related articles for article (PubMed ID: 25882890)
1. How to manage an isolated elevated PTH?
Souberbielle JC; Cavalier E; Cormier C
Ann Endocrinol (Paris); 2015 May; 76(2):134-41. PubMed ID: 25882890
[TBL] [Abstract][Full Text] [Related]
2. Different PTH response to oral peptone load and oral calcium load in patients with normocalcemic primary hyperparathyroidism, primary hyperparathyroidism, and healthy subjects.
Invernizzi M; Carda S; Righini V; Baricich A; Cisari C; Bevilacqua M
Eur J Endocrinol; 2012 Oct; 167(4):491-7. PubMed ID: 22872468
[TBL] [Abstract][Full Text] [Related]
3. [Normocalcemic primary hyperparathyroidism].
Spivacow FR; Sapag Durán A; Zanchetta MB
Medicina (B Aires); 2014; 74(6):457-61. PubMed ID: 25555006
[TBL] [Abstract][Full Text] [Related]
4. New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study.
Guo Y; Wang Q; Lu C; Fan P; Li J; Luo X; Chen D
BMC Endocr Disord; 2020 Jan; 20(1):5. PubMed ID: 31914999
[TBL] [Abstract][Full Text] [Related]
5. Normocalcemic primary hyperparathyroidism.
Cusano NE; Cetani F
Arch Endocrinol Metab; 2022 Nov; 66(5):666-677. PubMed ID: 36382756
[TBL] [Abstract][Full Text] [Related]
6. IDENTIFYING PARATHYROID HORMONE DISORDERS AND THEIR PHENOTYPES THROUGH A BONE HEALTH SCREENING PANEL: IT'S NOT SIMPLE VITAMIN D DEFICIENCY!
Majid H; Khan AH; Riaz M; Karimi H; Talati J
Endocr Pract; 2016 Jul; 22(7):814-21. PubMed ID: 27018622
[TBL] [Abstract][Full Text] [Related]
7. Calcium homeostasis and hyperparathyroidism: Nephrologic and endocrinologic points of view.
Lemoine S; Figueres L; Bacchetta J; Frey S; Dubourg L
Ann Endocrinol (Paris); 2022 Aug; 83(4):237-243. PubMed ID: 35598638
[TBL] [Abstract][Full Text] [Related]
8. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria.
Coe FL; Canterbury JM; Firpo JJ; Reiss E
J Clin Invest; 1973 Jan; 52(1):134-42. PubMed ID: 4682379
[TBL] [Abstract][Full Text] [Related]
9. Primary hyperparathyroidism.
Silva BC; Cusano NE; Bilezikian JP
Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):593-607. PubMed ID: 30449543
[TBL] [Abstract][Full Text] [Related]
10. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone.
Maruani G; Hertig A; Paillard M; Houillier P
J Clin Endocrinol Metab; 2003 Oct; 88(10):4641-8. PubMed ID: 14557434
[TBL] [Abstract][Full Text] [Related]
11. Reduced parathyroid hormone-stimulated 1,25-dihydroxyvitamin d production in vitamin d sufficient postmenoposual women with low bone mass and idiopathic secondary hyperparathyroidism.
Streeten EA; Rogstad AS; Flammer KM; Zarbalian K; Ryan K; Horwitz M; Holick MF; Shelton J
Endocr Pract; 2013; 19(1):91-9. PubMed ID: 23186957
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and primary hyperparathyroidism (PHPT).
Souberbielle JC; Bienaimé F; Cavalier E; Cormier C
Ann Endocrinol (Paris); 2012 Jun; 73(3):165-9. PubMed ID: 22677209
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and Management of Elevated Parathyroid Hormone Levels in Normocalcemic Patients.
Cusano NE
Med Clin North Am; 2021 Nov; 105(6):1135-1150. PubMed ID: 34688419
[TBL] [Abstract][Full Text] [Related]
14. [Hyperparathyroidism--new aspects].
Kruse A; Beige J
Ther Umsch; 2007 May; 64(5):265-9. PubMed ID: 17685085
[TBL] [Abstract][Full Text] [Related]
15. [Normocalcemic primary hyperparathyroidism: a growing problem].
Martínez Díaz-Guerra G; Guadalix Iglesias S; Hawkins Carranza F
Med Clin (Barc); 2013 Aug; 141(3):125-9. PubMed ID: 23199831
[TBL] [Abstract][Full Text] [Related]
16. [Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area].
Karlsson SL; Indridason OS; Franzson L; Sigurdsson G
Laeknabladid; 2005 Feb; 91(2):161-9. PubMed ID: 16155312
[TBL] [Abstract][Full Text] [Related]
17. Expanding the net: The re-evaluation of the multidimensional nomogram calculating the upper limit of normal PTH (maxPTH) in the setting of secondary hyperparathyroidism and the development of the MultIdimensional Predictive hyperparaTHyroid model (Mi-PTH).
Rajhbeharrysingh U; El Youssef J; Leon E; Lasarev MR; Klein R; Vanek C; Mattar S; Berber E; Siperstein A; Shindo M; Milas M
Surgery; 2016 Jan; 159(1):226-39. PubMed ID: 26531237
[TBL] [Abstract][Full Text] [Related]
18. Primary hyperparathyroidism.
Muñoz-Torres M; García-Martín A
Med Clin (Barc); 2018 Mar; 150(6):226-232. PubMed ID: 28992983
[TBL] [Abstract][Full Text] [Related]
19. Normocalcemic, subclinical, asymptomatic primary hyperparathyroidism in patients with goiter or papillary thyroid cancer--preliminary report. Normocalcemic primary hyperparathyroidism and thyroid pathology.
Niedźwiecki S; Kuzdak K; Kaczka K; Pomorski L
Wiad Lek; 2007; 60(5-6):228-30. PubMed ID: 17966885
[TBL] [Abstract][Full Text] [Related]
20. Normocalcemic primary hyperparathyroidism.
Cusano NE; Silverberg SJ; Bilezikian JP
J Clin Densitom; 2013; 16(1):33-9. PubMed ID: 23374739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
